BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36909341)

  • 1. Poor glycaemic control and ectopic fat deposition mediates the increased risk of non-alcoholic steatohepatitis in high-risk populations with type 2 diabetes: Insights from Bayesian-network modelling.
    Waddell T; Namburete A; Duckworth P; Fichera A; Telford A; Thomaides-Brears H; Cuthbertson DJ; Brady M
    Front Endocrinol (Lausanne); 2023; 14():1063882. PubMed ID: 36909341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The roles of type 2 diabetes and obesity in disease activity and progression of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
    Shinde S; Nelson DR; Mitroi J; Heaton PC; Hincapie AL; Brouwers B
    Curr Med Res Opin; 2024 Jan; 40(1):59-68. PubMed ID: 37933187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis.
    Andersson A; Kelly M; Imajo K; Nakajima A; Fallowfield JA; Hirschfield G; Pavlides M; Sanyal AJ; Noureddin M; Banerjee R; Dennis A; Harrison S
    Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2451-2461.e3. PubMed ID: 34626833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis.
    Dennis A; Kelly MD; Fernandes C; Mouchti S; Fallowfield JA; Hirschfield G; Pavlides M; Harrison S; Chakravarthy MV; Banerjee R; Sanyal A
    Front Endocrinol (Lausanne); 2020; 11():575843. PubMed ID: 33584535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian networks and imaging-derived phenotypes highlight the role of fat deposition in COVID-19 hospitalisation risk.
    Waddell T; Namburete AIL; Duckworth P; Eichert N; Thomaides-Brears H; Cuthbertson DJ; Despres JP; Brady M
    Front Bioinform; 2023; 3():1163430. PubMed ID: 37293292
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes.
    Lembo E; Russo MF; Verrastro O; Anello D; Angelini G; Iaconelli A; Guidone C; Stefanizzi G; Ciccoritti L; Greco F; Sessa L; Riccardi L; Pompili M; Raffaelli M; Vecchio FM; Bornstein SR; Mingrone G; Gastaldelli A; Capristo E
    Diabetes Metab; 2022 Sep; 48(5):101363. PubMed ID: 35760372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ectopic and Visceral Fat Deposition in Lean and Obese Patients With Type 2 Diabetes.
    Levelt E; Pavlides M; Banerjee R; Mahmod M; Kelly C; Sellwood J; Ariga R; Thomas S; Francis J; Rodgers C; Clarke W; Sabharwal N; Antoniades C; Schneider J; Robson M; Clarke K; Karamitsos T; Rider O; Neubauer S
    J Am Coll Cardiol; 2016 Jul; 68(1):53-63. PubMed ID: 27364051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
    Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
    JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
    Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
    BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
    Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
    J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD.
    Linge J; Ekstedt M; Dahlqvist Leinhard O
    JHEP Rep; 2021 Feb; 3(1):100197. PubMed ID: 33598647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity.
    Nachit M; Kwanten WJ; Thissen JP; Op De Beeck B; Van Gaal L; Vonghia L; Verrijken A; Driessen A; Horsmans Y; Francque S; Leclercq IA
    J Hepatol; 2021 Aug; 75(2):292-301. PubMed ID: 33865909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between Visceral Adipose Tissue and Non-Alcoholic Steatohepatitis Histology in Patients with Known or Suspected Non-Alcoholic Fatty Liver Disease.
    Idilman IS; Low HM; Gidener T; Philbrick K; Mounajjed T; Li J; Allen AM; Yin M; Venkatesh SK
    J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34200525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity.
    Barchetta I; Enhörning S; Cimini FA; Capoccia D; Chiappetta C; Di Cristofano C; Silecchia G; Leonetti F; Melander O; Cavallo MG
    BMC Med; 2019 Apr; 17(1):85. PubMed ID: 31035998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NIS2+™, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: A prospective derivation and validation study.
    Harrison SA; Ratziu V; Magnanensi J; Hajji Y; Deledicque S; Majd Z; Rosenquist C; Hum DW; Staels B; Anstee QM; Sanyal AJ
    J Hepatol; 2023 Sep; 79(3):758-767. PubMed ID: 37224923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease in pediatric type 2 diabetes: Metabolic and histologic characteristics in 38 subjects.
    Newfield RS; Graves CL; Newbury RO; Schwimmer JB; Proudfoot JA; Say DS; Feldstein AE
    Pediatr Diabetes; 2019 Feb; 20(1):41-47. PubMed ID: 30467936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Well-controlled versus poorly controlled diabetes in patients with obesity: differences in MRI-evaluated pancreatic fat content.
    Yu X; Huang YH; Feng YZ; Cheng ZY; Cai XR
    Quant Imaging Med Surg; 2023 Jun; 13(6):3496-3507. PubMed ID: 37284104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
    Harrison SA; Gawrieh S; Roberts K; Lisanti CJ; Schwope RB; Cebe KM; Paradis V; Bedossa P; Aldridge Whitehead JM; Labourdette A; Miette V; Neubauer S; Fournier C; Paredes AH; Alkhouri N
    J Hepatol; 2021 Aug; 75(2):284-291. PubMed ID: 33746083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex influences the association between appendicular skeletal muscle mass to visceral fat area ratio and non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
    Li G; Rios RS; Wang XX; Yu Y; Zheng KI; Huang OY; Tang LJ; Ma HL; Jin Y; Targher G; Byrne CD; Pan XY; Zheng MH
    Br J Nutr; 2022 Jun; 127(11):1613-1620. PubMed ID: 34176541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes.
    León-Mimila P; Villamil-Ramírez H; Li XS; Shih DM; Hui ST; Ocampo-Medina E; López-Contreras B; Morán-Ramos S; Olivares-Arevalo M; Grandini-Rosales P; Macías-Kauffer L; González-González I; Hernández-Pando R; Gómez-Pérez F; Campos-Pérez F; Aguilar-Salinas C; Larrieta-Carrasco E; Villarreal-Molina T; Wang Z; Lusis AJ; Hazen SL; Huertas-Vazquez A; Canizales-Quinteros S
    Diabetes Metab; 2021 Mar; 47(2):101183. PubMed ID: 32791310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.